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Summary
Inflammation and immunity may be associated with endothelial cell (EC) injury and thrombus
formation. We explored the mechanisms through which a humoral immune response directed
against the endothelium might promote coagulation. Using the interaction ofanti-EC antibod-
ies and complement (C) with cultured EC as a model, we studied the expression and function
of tissue factor, a cofactor for factor VIIa-mediated conversion offactor X to Xa. Exposure of
EC to anti-EC antibodies and C in sublytic amounts stimulated the synthesis of tissue factor
over a period of 16-42 h. Cell surface expression of tissue factor activity required activation of
C and assembly of the membrane attack complex, because expression was inhibited by soluble
CR1 and was not detected in the absence of C8. Elaboration of tissue factor messenger RNA
was observed over a period of 8-30 h and required protein synthesis. Expression of tissue factor
was not a direct consequence of the action of C on the EC but was a secondary response that
required as an intermediate step the release of interleukin 1o, an early product of the EC re-
sponse to C activation. These findings suggest that, after the assembly ofmembrane attack com-
plex on EC, the production of tissue factor and initiation of coagulation in a blood vessel de-
pend on the production ofinterleukin la and on its availability to stimulate affected EC.
V
ascular endothelium plays a central role in regulating
hemostasis and thrombosis. Hemostatic balance is
achieved through the interplay of endothelial cell (EC)'-
associated anticoagulant functions, such as heparan sulfate--
antithrombin III (1), thrombomodulin (2), and tissue factor
pathway inhibitor (3), and procoagulant functions, such as
tissue factor (4) and plasminogen activator inhibitor (5). In
response to inflammatory mediators such as histamine, IL-1,
and TNF (6-9), and noxious agents such as endotoxin (10-
12), endothelium adopts a procoagulant posture in which the
assembly ofprothrombinase is enhanced, inhibition ofthrom-
bin is attenuated, and endothelium becomes adherent toward
platelets (13). These changes are also associated with the se-
cretion of cytokines and the increased expression of cell ad-
hesion molecules and may be called collectively EC "acti-
vation."
Presumably, the regulation of coagulation and hemostasis
is perturbed in immune reactions. In the Arthus reaction,
for example, deposition ofimmune complexes in small blood
vessels is followed by formation of fibrin thrombi (14).
While the procoagulant changes in the Arthus reaction may
be caused in part by the action of neutrophils on endothe-
'Abbreviations used in this paper: EC, endothelial cell; MRNA, messenger
RNA; RT, reverse transcriptase.
lium (15), it is not unlikel'y that the direct action of C on
endothelium also plays a role. Consistent with this concept,
the pathology of vasculitides such as systemic lupus erythe-
matosis, serum sickness, and rheumatoid arthritis (16-19), in
which neutrophils are less critically involved, is also charac-
terized by fibrin deposits in affected vessels. Perhaps the most
extreme example of an immune-mediated reaction associ-
ated with widespread coagulation is acute vascular rejection
ofxenografts, in which the reaction of antidonor antibodies
and C with endothelium over a period of hours or days re-
sults in widespread intravascular coagulation and thrombo-
sis (20).
One mechanism by which immune-mediated inflamma-
tion might cause prothrombotic changes is alteration of the
barrier properties of endothelium. Exposure of endothe-
lium to IL-1, TNF, and C5b67 causes the formation ofin-
tercellular "gaps" (21-23) that expose tissue factor in the
underlying matrix to plasma clotting factors . Tissue factor
then interacts with coagulation factor VIla to promote as-
sembly ofthe prothrombinase complex (Va and Xa), which
in turn catalyzes conversionofprothrombin to thrombin. In
many cases, these gaps are found to be transient; thus, while
they may explain acute changes in hemostatic function (21-
23), they may not account for the more persistent procoag-
ulant condition of blood vessels in immune complex-
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result from the synthesis and elaboration of tissue factor by
EC. EC exposed to IL-1 and TNF up-regulate expression of
tissue factor and manifest increased procoagulant activity
through this mechanism (6, 8) . The goal of studies reported
here was to determine whether endothelium would respond
to C by synthesizing tissue factor, as it does after exposure
to other inflammatory mediators. To this end, we assessed
the response of porcine EC to anti-EC antibodies and C,
modeling the conditions thought to lead to acute vascular
rejection of an organ graft. We report here that C does in-
duce the expression of tissue factor as determined by up-
regulation of messenger RNA (mRNA) and elaboration of
membrane-associated tissue factor activity. However, un-
like the response to IL-1 and TNF, EC's up-regulation of
tissue factor is not a primary response to C, but, rather, it
requires the synthesis and release of IL-la as an intermedi-
ate step.
Materials and Methods
Materials.
￿
DMEM, L-glutamine, penicillin, streptomycin, phe-
nol, guanidinium thiocyanate, and Moloney murine leukemia vi-
rus reverse transcriptase (RT) were from Life Technologies (Gaith-
ersburg, MD). Sodium barbital, diethyl pirocarbonate, gelatin (type
B, from bovine skin), BSA (fraction V), glutaraldehyde, Limulus
amebocyte lysate, endotoxin (LPS, Escherichia coli serotype 0111:
B4; stimulation index 4.5/1 k,g), andalkaline phosphatase-conju-
gated antibodies came from Sigma Chemical Co. (St. Louis, MO).
FCS was from HyClone Laboratories, Inc. (Logan, UT). Human
serum immunodepleted of C8, purified human C8, purified hu-
man rC5a, and mouse mAbs specific for a neoantigen on iC3b
were from Quidel (San Diego, CA). Pyrogen-free inulin was
from ICNBiomedicals, Ltd. (Costa Mesa, CA). Spectozyme FXa
(MeO-CO-D-CHG-GIy-Arg-pNA.AcOH) was purchased from
American Diagnostica Inc. (Greenwich, CT). Purified human fac-
tor VIIa, factor X, and factor Xa were obtained from Enzyme
Research Laboratories, Inc. (South Bend, IN). Deoxynucleotide
triphosphates, oligo d(T)16, and AmpliTaq DNA polymerase were
from Perkin-Elmer Cetus Corp. (Norwalk, CT). Random hexa-
nucleotide primer was from Boehringer Mannheim Corp. (India-
napolis, IN), and RNasin was from Promega Corp. (Madison,
WI). Human rIL-1a was from Genzyme (Cambridge, MA). Oli-
gonucleotide primers were synthesized by Operon Technologies,
Inc. (Alameda, CA). [a32P]dCTP was from DuPont-New En-
gland Nuclear (Wilmington, DE). Soluble CR1 was a gift of
T-Cell Sciences (Cambridge, MA). IL-1 receptor antagonist and
anti-human IL-1a neutralizing antibodies were from R&D Sys-
tems, Inc. (Minneapolis, MN). Recomb protein A/G was ob-
tained from Pierce (Rockford, IL).
EC Culture.
￿
Porcine aortic EC were isolated, characterized,
andcultured as described previously (23, 24). EC monolayers (pas-
sages 3-6) were grown to confluence on gelatin-coated 6-well,
24-well, and 96-well plates and were maintained in DME with
10% FCS for 48-72 h before each experiment.
Anti-ECAntibodies and C.
￿
Samples of human, porcine, and
rabbit bloodwere used as sources ofantibodies andC. Blood was
collected in sterile, pyrogen-free containers and allowed to clot at
4°C, and the serum fraction was separated and stored in plastic
vessels. The Limulus amebocyte lysate test (25) was used to detect
endotoxin contamination of the sera and purified serum compo-
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nents. Human serum used as a source of anti-EC antibodies was
heated to 56°C for30 min to inactivate C. The titerofantibodies
in serum was determined by ELISA as describedpreviously using
the cultured porcine EC as a target (26). Anti-porcine EC anti-
bodies were isolated from human serumby adsorption to cultured
EC followed by thermal extraction as described previously (27).
A rabbit antiserum was raised against porcine EC, and the IgG
antibodies in that serum were affinity isolated using a Recomb
protein A/G column as describedby the manufacturer. For some
experiments, a human serum that contained very low or unde-
tectable levels of natural anti-porcine EC antibodies (28), or that
was immunodepleted ofIgM and C1q restored (29), was used as a
source of human C. C activation was determined by measuring
deposition of iC3b neoantigen on EC by ELISA, using mouse
monoclonal anti-human iC36 antibodies as described (23).
Procoagulant and Tissue FactorActivity ofEC.
￿
To determine pro-
coagulant activity, monolayers ofconfluentEC (^"105) were either
scraped to obtain a suspension or kept intact and examined for
procoagulant activity (11). Single-stage clotting assays were per-
formed by adding to the cells 0.1 ml clotting buffer consisting of
7.7 mM sodium barbital, 12.8 mM sodium acetate, and 140 mM
NaCl, pH 7.4. 0.1 ml citrated human or porcine plasma and 20
mM calcium chloride were added, and the time required for the
first visual evidence offibrin clot at 37°C was determined. Tissue
factor activity expressed by porcine EC was assessed based on the
generation of factor Xa from human factor X in the presence of
10 nM human factor VIIa, as described (30) . Tissue factor activity
was determined in the extracellular matrix by treating EC mono-
layers for 10 min with 0.1 M NH40H to remove EC and expose
the extracellular matrix (31). The generation of factor Xa, as a
measure oftissue factor expression, was compared with astandard
curve generated usingpurified factor Xa.
Analysis of Tissue Factor, IL-1a, and ~6-actin mRNA by PCR.
RNA from porcine aortic EC was isolated by the guanidinium
thiocyanate method (32). The cDNA synthesis and PCR reac-
tions were performed in a PCR machine (model 9600; Perkin-
Elmer Cetus Corp.) in reaction conditions recommended by the
manufacturer. The amplified products were autoradiographed and
quantitated using a scanner (model 9600; Relisys, Milpitas, CA) and
software (Image 1.43; National Institutes of Health Shareware, Be-
thesda, MD). The PCR conditions for [3-actin and tissue factor
were 94°C for20 s, 55°C for 20 s, and 72°C for75 s, for25 and 30
cycles, respectively. The sequences of primers for [3-actin were
5'ATGTTTGAGACCTTCAACAC3' and 5'CACGTCACA-
CTTCATGATGGA3' (33), and for tissue factor were 5'TTC-
AAGAC[A/C]ATT[T/CJTGGAGTGG3' and 5'AGGGGGAGT-
TGGTAAAC3' (34). The design of primers for tissue factor was
based on the sequence of porcine tissue factor, which we ob-
tained by cloning tissue factor cDNA from porcine EC treated
with endotoxin (not shown here). The PCR conditions forpor-
cine IL-la were 94°C for 20 s and 63°C for 20 s for 30 cycles.
The sequences ofprimers for IL-Ice were 5'GCAGCCACCGGG-
AAGATTCTG3' and 5'GTACATACGGCCTGTCAACAC3'
(accession No. M86730). All PCR products, except [3-actin, were
confirmedby sequencing (not shown) . To compare relative levels
of tissue factor, and IL-la mRNA to [3-actin mRNA, a semi-
quantitative RT-PCR strategy was used. First, cDNA for each
sample was examined for [3-actin mRNA, and concentrations of
cDNA were adjusted to generate approximately equal R-actin
PCR products. This information was used as a guide to deter-
mine the amount ofcDNA used forexamination ofotherspecific
genes. Tissue factor and IL-1a PCR products, from EC stimu-
lated with anti-EC antibodies plus C, human rIL-lot, or endo-Figure 1 .
￿
Induction of coagulant
activity inEC by anti-EC antibodies
and C . Coagulant activity was mea-
sured by determining clotting time
of porcine plasma applied to porcine
EC . EC treated for 16 h with 10%
human serum containing natural
anti-EC antibodies and C (Ab+C)
showed increased coagulant activity
compared with control cells (Cons) .
EC exposed to heat-inactivated serum (Ab+C, 56C) or to human C (se-
rum lacking anti-porcine EC antibodies, C) had coagulant activity similar
to that of controls .
Results
toxin, were generated from ^500-1,000 ng ofcDNA, in accord
with the (3-actin PCR results .
Induction of Procoagulant Activity in EC by Antibodies and
C. To ascertain whether humoral reactions might induce
procoagulant activity in endothelium, porcine EC mono-
layers were exposed to human serum containing natural
anti-porcineEC antibodies and C . Fig. 1 depicts a represen-
tative experiment in which an increase in coagulant activity,
indicated by a decrease in plasma clotting time, was observed
16 h after exposure of porcine EC to 10% human serum, a
concentration that yields no detectable cytotoxicity (23) .
EC treated with the same serum that had been heated to
56°C to inactivate C did not decrease plasma clotting time,
suggesting that anti-porcine EC antibodies alone do not
induce procoagulant activity (Fig . 1) . Furthermore, a serum
that lacked anti-porcine EC antibodies but had intact C
was ineffective ; therefore, the manifestation of procoagu-
lant activity in this system is neither a function ofserum re-
sponse seen in fibroblasts (35, 36) nor a response to con-
taminants such as endotoxin (8, 10) .
Contribution of Tissue Factor to Procoagulant Activity ofEC.
The contribution of tissue factor to the increased coagulant
activity o£EC was evaluated by measuring the conversion
offactor X to Xa in the presence of excess factor VIIa after
stimulation ofEC by anti-EC antibodies and C . In repeated
experiments, exposure of 104 porcine EC to human natural
antibodies and C caused a very significant increase in con-
version ofX to Xa (Fig . 2) . We concluded that the conver-
sion of factor X to Xa in this system was not catalyzed by a
cellular protease, because it was not observed in the ab-
sence of factor VIla .
Dose Response and Kinetics of Tissue Factor Activity in EC in
Response to Anti-EC Antibodies and C . Tissue factor activ-
ity ofEC exposed to serum containing anti-EC antibodies
A
￿
B
% Serum
￿
Time (Hours)
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Figure 2 .
￿
Role of tissue factor in ex-
41
￿
o x
￿
pression of procoagulant activity . EC
J
￿
monolayers were exposed to 10% hu-
c 3l vua+x man serum containing natural anti-EC
2
_
X
￿
I
￿
antibodies and C (Ab+C) for 16 h or
t"
￿
were untreated (Cont) and were exam-
ined for expression of tissue factor activ-
ity based on conversion of factor X to
Xa in the presence offactor VIIa, as described in Materials and Methods .
Stimulated EC mediated generation of Xa only in the presence of VIIa
and X (") but not in the presence ofXalone (O) .
and C depended on the concentration of serum used . Fig.
3 A shows a representative response . Tissue factor activity
observed in porcine EC after stimulation with a sublytic
concentration ofhuman serum containing anti-EC antibod-
ies plus C increased progressively during the course of 42 h
(Fig . 3 B) . The rate of tissue factor activity was a reflection
of the amount of anti-EC antibodies and C used to stimu-
late EC .
Role ofAntibodies and Activation ofC in Induction of Tissue
Factor Activity in EC. As shown in Fig . 4, the procoagu-
lant activity of porcine EC stimulated with human serum
was dependent on the amount ofC activation, as assessed by
deposition ofiC3b neoantigen on the cells, a linear function
ofIgM recognizing ei-galactose on porcine EC (23, 27, 37) .
Thus, a serum with a significant level of anti-EC antibodies
decreased clotting time as a function ofIgM and C activa-
tion (Fig. 4 A), whereas a serum free of these antibodies
neither activated C nor decreased coagulation time at any
concentration (Fig . 4 B) . The requirement for C activation
was also demonstrated by the findings that (a) neither puri-
fied anti-EC antibodies nor C alone induced a change in
clotting time by EC ; and (b) procoagulant activity was not
observed in EC treated with serum in which C activity was
abolished by heating to 56°C or with serum combined
with sCR1, which inhibits C3 convertases (Fig . 4 C) (38) .
Thus, the interaction ofIgM with EC does not by itself al-
ter the coagulant activity of EC as studied here, but IgM
binding is needed to activate C, which, in turn, increases
the procoagulant activity ofEC .
Several lines of evidence suggested that induction of tis-
sue factor activity in this system was not mediated by C5a
(Fig . 5) . First, exposure ofEC to recombinant C5a in the
absence or presence of anti-EC antibodies did not stimulate
tissue factor activity as measured by conversion o£factor X
to Xa . Second, exposing EC to native C5a, generated by ac-
tivation ofC by pyrogen-free inulin, failed in repeated ex-
periments to stimulate porcine EC expression oftissue fac-
Figure 3 .
￿
Dose response and kinetics ofprocoagulant
activity induced by natural antibodies andC . Monolayers
ofEC were treated with human natural anti-EC antibod-
ies plus C, and tissue factor activity was determined based
on conversion offactorX to Xa in the presence offactor
VIIa . (A) Dose response ofcoagulant activity induced by
natural and-EC antibodies and C.EC were treated for 16 h
with various concentrations ofantibodies and C. (B) Ki-
netics ofcoagulant activity induced by natural antibodies
and C. EC treated with antibodies andC (-<D-) or with
1,600 U/ml human rIL-la (-4--) for indicated periods .Figure 4.
￿
Role of C activation
in induction of coagulant activity
in EC. Cultured porcine EC
treated with human natural anti-
EC antibodies and C were exam-
ined for coagulant activity deter-
mined by the clotting time (CT,
PCA) of porcine plasma. (A) In-
duction of coagulant activity as a
function of IgMbinding and C ac-
tivation. EC were treated with in-
creasing amounts ofanti-EC antibodies and C andexamined for coagulant activity. Binding of IgM to EC (IgA and activation of C (iC3b) on EC was
measured by ELISA. (B) Lack ofcoagulant activity in the absence of IgM binding and C activation. EC were treated with serum lacking anti-EC anti-
bodies and examined as in A. (C) Requirement for complement activation in induction ofcoagulant activity. EC were exposed for 16 h to affinity-puri-
fied human natural anti-EC antibodies (XAb), serum lacking human anti-EC antibodies (C), antibodies and C to which sCRI was added
(Ab+C+sCR1), or serum that washeated to 56°C (Ab+C, 56°C). EC treated under conditions in which C was not activated had the same coagulant
activity as controls (Coat) .
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for activity. However, expression of tissue factor by EC in
this system required assembly of the membrane attack com-
plex, because pooled human serum depleted of C8 plus pu-
rified anti-EC antibodies did not mediate tissue factor ac-
tivity, whereas this C8-depleted serum reconstituted with
purified C8 did so .
The induction of tissue factor in endothelium was not
restricted to stimulation of EC by xenoreactive natural an-
tibodies and C. Incubation of porcine EC with rabbit IgG
specific for porcine EC in combination with human C also
induced significant tissue factor activity (Fig. 6). Moreover,
tissue factor expression in porcine EC was induced in re-
sponse to rabbit anti-porcine EC antibodies plus porcine
serum (homologous C), although the amount of tissue fac-
tor produced under these conditions wasless than theamount
produced by human C (Fig. 6) . On the other hand, preim-
mune IgG either alone or in combination with porcine or
human C did not mediate tissue factor activity (Fig. 6).
Cellular Localization of Tissue Factor Activity.
￿
Cellular lo-
calization of tissue factor was evaluated by comparing the
ability of intact EC to generate conversion of factor X to
Xa with that of "extracellular matrix." As Fig. 7 A shows,
most of the tissue factor activity induced in cultured por-
Cont Ab+C C C+ C5a C5a+ Ab+ Ab+ C8
Inulin
￿
Ab AC8 AC8+C8
r1.5
d
0.5v
0
Figure 5.
￿
Role of membrane attack complex in expression of tissue
factor by EC. Porcine EC were stimulated with various components of C
for 18 h and examined for tissue factor activity based on conversion of
factor X to Xa in the presence offactor VIIa. EC exposed to intact C, C
activated by 10 mg/inl mulm (C+Inulin), or 500 ng/ml recombinant hu-
man C5a in the absence or presence ofantibodies (C5a + Ab) had tissue
factor activity similar to that of untreated EC (Coot) . EC treated with 0.4
ltg/ml purified rabbit anti-porcine EC antibodies (Ab+) plus human se-
rum immunodepleted of C8 (dC8) did not exhibit tissue factor activity;
however, EC treated with these reagents plus purified C8 did so.
1810
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cine EC by antibodies and C was observed on the surface
ofintact EC and not in the extracellular matrix. Since the
method used to expose extracellular matrix leaves behind
some ofthe basal cell membrane, it is likely that tissue fac-
tor activity was present on both the apical and basal mem-
branes. Tissue factor activity also was not localized to the
intracellular compartment, because stimulated EC subjected
to repeated cycles of freezing and thawing had the same
level of tissue factor activity as control cells (Fig. 7 B).
Expression of Tissue Factor mRNA by EC Induced by Anti-
bodies and C. The effect of anti-EC antibodies and C on
the level of tissue factor mRNA in EC was evaluated by
PCR. Fig. 8 A depicts a representative experiment show-
ing expression of tissue factor mRNA in EC stimulated by
natural antibodies and C. Tissue factor mRNA was first de-
tected 8 hafter stimulation, reaching maximum levels at 12 h.
These findings differ from the results obtained after EC were
stimulated by endotoxin, where tissue factor mRNA was de-
tected as early as 2 h. Serum factors other than antibodies
and C did not mediate this response, since neither serum
lacking anti-EC antibodies nor serum in which C was inac-
tivated up-regulated tissue factor mRNA (Fig. 8 B).
Induction of Tissue Factor by Antibodies and CIs Not an Ear-
ly Response. As demonstrated in Fig. 8, endotoxin induced
tissue factor mRNA more rapidly than did C, suggesting that
a mechanism of induction by optimum amounts ofC differs
from endotoxin-mediated immediate early responses (39, 40) .
That tissue factor mRNA is not elaborated as an immediate
early gene in EC stimulated with C was substantiated by
the finding that tissue factor mRNA in our system was not
increased in the presence of cycloheximide. However, cy-
Figure 6.
￿
Induction of tissue fac-
tor activity in EC by rabbit anti-EC
IgG. Tissue factor activity in porcine
EC was examined after treatment of
the cells with rabbit anti-porcine EC
antibodies in combination with por-
cine C or human complement. EC
were incubated with 0.4 llg/ml pu-
IgG
￿
IgG+PC IgG+HC
￿
rified preitmnune (PIN!) or immune
(IM rabbit IgG in the absence of C or in combination with either 10%
porcine C (PC) or 10% human C (HC) for 18 h and examined for tissue
factor activity.
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Figure 7 .
￿
Cellular localization of tissue factor. Porcine EC treated with
human natural anti-EC antibodies and C and examined for tissue factor
activity. (A) Comparison oftissue factor activity on cell surface (" ) versus
extracellular matrix (D) . EC were treated with 20% human serum for in-
dicated periods of time and examined for tissue factor activity based on
conversion offactorX to Xa in the presence of factor VIIa . Tissue factor
activity was detected on the cell surface . (B) Comparison of coagulant ac-
tivity of intactEC (O) and that of EC cytoplasmic components (" ) . EC
treated for 20 h with 20% serum were subjected to repeated freezing and
thawing, and coagulant activity was determined by the clotting time ofpor-
cine plasma applied to EC . Most coagulant activity is on the cell mem-
brane .
cloheximide increased tissue factor mRNA induced with
IL-1a (Fig . 9) .
Release of EC-stimulating Factors .
￿
Since the induction of
tissue factor mRNA by antibodies and C required protein
synthesis, as the experiments shown in Fig. 9 demonstrate,
it was possible that the induction of tissue factor might in
fact be a secondary response to some primary product of
EC . We tested this idea by asking whether the medium
from EC treated with anti-EC antibodies and C contained
factors other than C that would induceEC to express tissue
factor activity . When such medium was removed 1 or 5 h
after stimulation ofEC and the monolayers were "chased"
by fresh medium, procoagulant activity notably decreased
(Fig. 10 A) . This decrease was not caused by the removal of
C ; the conditioned medium had little C activity (Fig. 10,
inset) . Also, although it contained little C activity, the con-
ditioned medium from EC stimulated with antibodies and
C for 5 h, induced procoagulant activity in new EC mono-
layers (Fig. 10 B) . The latter was not the effect of residual
C activity in the conditioned medium because addition of
sCR1 to the conditioned medium did not inhibit the abil-
ity of the medium to induce tissue factor activity . Thus, con-
ditioned medium, generated by addition of antibodies and
Figure 9.
￿
Role ofprotein synthesis
in expression oftissue factor mRNA.
EC were untreated (A), exposed to
10% human natural antibodies and C
(B), or exposed to 800 U/ml IL-la
(C) in the presence (+) or absence
(-) of cycloheximide (CHX) for 4 h . RNA was then extracted, and the
cDNA for tissue factor and (3-actin was amplified byPCR as described in
Materials and Methods . In contrast to EC treated with IL-1a, EC treated
with anti-EC antibodies and C do not show an increase in tissue factor
mRNA in the presence of cyclohexirnide, indicating that tissue factor is
not an early response .
C to EC, contains an intermediary agent responsible for the
induction of tissue factor activity .
A series of experiments revealed that the identity of this
intermediate agent was IL-1a . First, treatment of porcine
EC with antibodies and C induced the expression ofIL-1a
mRNA within 2 h (Fig. 11 A), and expression of IL-lot
mRNA in this way was an immediate early response because
it increased markedly when cycloheximide was present (Fig.
11 B) . Second, IL-1 receptor antagonist eliminated the pro-
coagulant response of EC treated with antibodies and C
(Fig. 12 A) . Third, as shown in Fig . 12 B, addition ofanti-
human IL-lot antibodies to EC treated with antibodies and
C in a dose-dependent manner decreased expression of tis-
sue factor activity .
Discussion
The maintenance of hemostatic balance by endothelium
is compromised in various types of humoral immune re-
sponses . For example, in the Arthus reaction, local deposi-
tion of immune complexes is associated with prominent
evidence of thrombosis in the microvessels (41) . Similarly,
necrotizing vasculitis, systemic lupus erythematosis, serum
sickness, and other clinical vasculitides are characteristically
associated with intravascular coagulation (16, 17) . Whereas
neutrophils or antiphospholipid antibodies may initiate throm-
bosis, in some cases the synthesis of tissue factor and elabo-
ration on the surface ofEC probably contribute to a proco-
agulant diathesis . The frequent association of coagulation
with assembly ofC complexes in the microvessels also sug-
gests a potential role ofC in up-regulation of tissue factor
activity in EC . Consistent with that concept, we report
that assembly of the membrane attack complex on EC in-
duces the synthesis and release of IL-la, which, as a potent
Figure 8.
￿
Induction of tissue factormRNA
in EC treated with human natural antibodies
and C . RNA fromEC was extracted, and the
mRNA for tissue factor and (3-actin were am-
plified by PCR as described in Materials and
Methods . (A) Comparison of tissue factor
mRNA expression in EC induced by human
natural antibodies and C versus endotoxin
(LPS) . EC were treated with 25% human an-
tibodies plus C or 25 IWg/ml LPS for indicated
periods and examined for expression of tissue
factor and R-actin mRNA . (B) Comparison of tissue factormRNA expression in EC induced by human natural antibodies and C versus C or antibodies
alone. EC were either treated for 24 h with 20% antibodies and C (Ctro, or were exposed for indicated periods to 20% C (C) or 20% antibodies (Ab) .
Tissue factormRNA is detected only in EC treated with antibodies and C .too
50-
0 0 .
0_50
O
Cont lhr 5 hr 16hr
￿
Ab+C CM CM+ Ab+C+ Cont
sCRI sCRI
Figure 10 .
￿
Release from EC ofa factor that stimulates production of
tissue factor . EC were treated with anti-EC antibodies and C and then
examined for coagulant activity based on clotting time ofporcine plasma
applied to porcine EC . (A) Dependence of tissue factor expression on
conditionedmedium. EC were treated with 20% antibodies andC for 16 h,
or for 1 h and 5 h, after which conditioned medium was chased with
DMEM + 1% FCS and incubation was continued for 15 and 11 h, re-
spectively. Removal ofconditionedmedium containing antibodies andC
from EC inhibited tissue factor expression . (B) Stimulation oftissue factor
production by conditioned medium. EC were treated for 16 h with anti-
bodies andC (Ab+C) or with conditioned medium obtained from EC
treated with antibodies and C for 5 h (CM) in the presence or absence of
sCRI . C activity was assessed by deposition of iC3b and is shown in
Ab+C andCM . Conditioned medium fromEC treated with antibodies
andC induced procoagulant activity in newEC independentofC activity.
Figure 11 .
￿
Up-regulation of IL-la mRNA mediated by human natu-
ral antibodies and C. RNA from EC was extracted and the cDNA for
IL-la and (3-actin were amplified by PCR as described in Materials and
Methods . (A) Kinetics of IL-la mRNA expression by EC . Porcine EC
were treated with 25%human natural anti-EC antibodies plus C for indi-
cated periods and examined for expression ofIL-lu and (3-actin mRNA .
(B) Early expression of IL-la mRNA in EC . EC were stimulated with
10% anti-EC antibodies andCor 800U/ml IL-la in the absence or pres-
ence of cycloheximide (CHX) for the indicated periods . EC treated with
human natural anti-EC antibodies plus C show an increase in IL-la
mRNA in the presence ofcycloheximide .
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Figure 12 .
￿
Role ofIL-1 in C-mediated tissue factor expression . (A) In-
hibition of tissue factor expression by IL-1 receptor antagonist . Porcine
EC were treated for 16 hwith 10%human natural anti-EC antibodies and
C in the presence ofincreasing concentrations ofIL-1 receptor antagonist
and then examined for coagulant activity by determining clotting time of
porcine plasma applied to porcine EC or expression of tissue factor and
IL-la mRNA by RT-PCR, as described in Materials and Methods. (B)
Inhibition oftissue factor expression by anti-IL-la antibodies . Porcine EC
were treated with 10% human natural anti-EC antibodies and C in the pres-
ence ofincreasing concentrations ofanti-human IL-la antibodies ((+) or
100 jig/ml of control (noninhibitory) antibodies (" ) for 16 h. Porcine
EC were then examined for tissue factor activity based on conversion of
factorX to Xa in the presence offactor VIIa .
intermediate, causes a remarkable increase in tissue factor ac-
tivity . Our findings suggest that the initiation ofintravascu-
Jar coagulation and generation of fibrin leading to formation
ofocclusive thrombi and necrosis in humoral immune reac-
tions may be caused in part by expression oftissue factor in
endothelium in response to the host's humoral immunity.
The system used in our experiments involved stimula-
tion ofEC by heterologous serum as a model for the reac-
tion that might occur in axenogeneic organ graft undergo-
ing acute vascular rejection, a type of rejection that develops
over a period of days after engraftment and that is charac-
terized by widespread intravascular coagulation (20) . The
prominent formation of fibrin thrombi in this setting sug-
gests that porcine tissue factor might be able to bind to hu-
man VIIa, initiating coagulation. Indeed, although porcine
tissue factor shows only 75% homology to its human coun-
terpart (not shown) and is not conserved in the factor VIIa
binding site, ou'r studies show that it interacts very effi-
ciently with human factor VIIa .
Expression of IL-1 and subsequent modulation of tissue
factor activity in this system probably reflect signaling by
the membrane attack complex (for review, see reference
42) . Assembly of the membrane attack complex in sublytic
amounts on B lymphoblastoid cells increases ceramide (43),
and on Ehrlich's ascites cells induces protein kinase C acti-
vation, and Cat' influx and increases the intracellular con-
centration ofcAMP (44) . While protein kinase C activation
in monocytes and increased intracellular levels of Cat + in
EC play a direct role in the expression of tissue factor
. .
Ab+C CM(45-47), ceramide and cAMP have been implicated in up-
regulation of IL-1 in various types of cells (48, 49). Al-
though the formation ofmembrane attack complex on EC is
clearly requisite for synthesis of tissue factor in the model
we studied, membrane attack complex assembly may not
be sufficient. Thus, other components of plasma may con-
tribute to this process.
Based on the findings reported here, a model for associa-
tion between humoral immunity and coagulation might be
proposed. In a humoral immune reaction, the membrane
attack complex induces EC to elaborate IL-1a, perhaps
through channels provided by membrane attack com-
plexes. Elaborated this way, IL-la can act on EC as well as
monocytes to up-regulate procoagulant activity. Blood flow
may be a critical determinant in this process. Rapid blood
flow may carry IL-la away from EC, limiting procoagu-
lant changes, while vasoconstriction, perhaps mediated by
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